Pancreatic cancer is one of the most lethal human malignancies with an all-stage 5-year survival frequency of <5%, which highlights the urgent need for more effective therapeutic strategies. We have previously shown that triptolide, a diterpenoid, is effective against pancreatic cancer cells in vitro as well as in vivo. However, triptolide is poorly soluble in water, limiting its clinical use. We therefore synthesized a water-soluble analog of triptolide, named Minnelide. The efficacy of Minnelide was tested both in vitro and in multiple independent yet complementary in vivo models of pancreatic cancer: an orthotopic model of pancreatic cancer using human pancreatic cancer cell lines in athymic nude mice, a xenograft model where human pancreatic tumors were transplanted into severe combined immunodeficient mice, and a spontaneous pancreatic cancer mouse model (KRasG12D; Trp53R172H; Pdx-1Cre). In these multiple complementary models of pancreatic cancer, Minnelide was highly effective in reducing pancreatic tumor growth and spread, and improving survival. Together, our results suggest that Minnelide shows promise as a potent chemotherapeutic agent against pancreatic cancer, and support the evaluation of Minnelide in clinical trials against this deadly disease.
A disodium phosphonooxymethyl
prodrug of the antitumor agent triptolide
was prepared from the natural product in three steps (39% yield) and
displayed excellent aqueous solubility at pH 7.4 (61 mg/mL) compared
to the natural product (17 μg/mL). The estimated shelf life
(t90) for hydrolysis of the prodrug at
4 °C and pH 7.4 was found to be two years. In a mouse model of
human colon adenocarcinoma (HT-29), the prodrug administered intraperitoneally
was effective in reducing or eliminating xenograft tumors at dose
levels as low as 0.3 mg/kg when given daily and at 0.9 mg/kg when
given less frequently. When given via intraperitoneal and oral routes
at daily doses of 0.6 and 0.9 mg/kg, the prodrug was also effective
and well tolerated in a mouse model of human ovarian cancer (A2780).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.